ESR1 and breast cancer: Concurrently, MEK (Fujii et al, 2011) and PI3K/AKT/MTOR (Ciruelos Gil, 2014) have been implicated as key primary resistance mechanisms in endocrine‐resistant ER+ breast cancers.